MedTrace Logo

Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma

NCT03137199 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2020-05-21

No results posted yet for this study

Summary

A Phase 1 investigation will be performed to test the safety of two doses of bone marrow-derived MSCs (20,000,000 and 100,000,000) administered via peripheral intravenous infusion.

Conditions

Interventions

BIOLOGICAL

hMSCs

intravenous infusion of bone marrow-derived allogeneic stem cells

Sponsors & Collaborators

  • The Marcus Foundation

    collaborator OTHER

  • Marilyn Glassberg

    lead OTHER

Principal Investigators

  • Marilyn K Glassberg, MD · University of Miami

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-22
Primary Completion
2020-03-03
Completion
2020-04-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03137199 on ClinicalTrials.gov